Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients

American Journal of Epidemiology

Volumn 174, Issue 9, 2011, Pages 1089-1099

  Huybrechts, Krista F ^a,b   Brookhart, M Alan ^c   Rothman, Kenneth J ^b,c,d   Silliman, Rebecca A ^b,e   Gerhard, Tobias ^f   Crystal, Stephen ^f   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

^c IL   (United States)

^d RTI HEALTH SOLUTIONS   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f RUTGERS UNIVERSITY   (United States)

Author keywords

antipsychotic agents; confounding factors (epidemiology); dementia; mortality; nursing homes; pharmacoepidemiology

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

COHORT ANALYSIS; COMPARATIVE STUDY; DATA SET; DRUG; EPIDEMIOLOGY; MEDICINE; MORTALITY; MULTIVARIATE ANALYSIS; RISK FACTOR;

AGED; ARTICLE; ATTRIBUTABLE RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FRAIL ELDERLY; HOSPITAL ADMISSION; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION THERAPY MANAGEMENT; MORTALITY; NURSING HOME PATIENT; PROPENSITY SCORE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HOMES FOR THE AGED; HUMANS; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NURSING HOMES; ODDS RATIO; PROPENSITY SCORE; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 80054926861     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr213     Document Type: Article

References (40)

1. Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957-970. (Pubitemid 351367549)
2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503): 2112-2117. (Pubitemid 41797645)
3. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry. 2000;15(suppl 1):S2-S4.
4. Liperoti R, Mor V, Lapane KL, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64(9): 1106-1112. (Pubitemid 37158258)
5. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med. 2005;165(11):1280-1285. (Pubitemid 40989593)
6. Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc. 2004; 52(5):749-755. (Pubitemid 38596494)
7. Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med. 2007; 167(7):676-683. (Pubitemid 46598460)
8. Chen Y, Briesacher BA, Field TS, et al. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89-95.
9. Rapoport M, Mamdani M, Shulman KI, et al. Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry. 2005;20(8):749-753. (Pubitemid 41158720)
10. Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA. 2005;293(20):2462. (Pubitemid 40705722)
11. Food and Drug Administration, US Department of Health and Human Services. Information for Healthcare Professionals: Conventional Antipsychotics. Silver Spring, MD: Food and Drug Administration; 2010. (http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm) . (Accessed May 3, 2010).
12. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5): 627-632. (Pubitemid 46426056)
13. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786. (Pubitemid 351650498)
14. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335-2341. (Pubitemid 41713745)
15. Food and Drug Administration, US Department of Health and Human Services. FDA Public Health Advisory: Deaths With Antipsychotics in Elderly Patients With Behavorial Disturbances. Washington, DC: Food and Drug Administration; 2005. (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171. htm). (Accessed May 3, 2010).
16. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337. (Pubitemid 40601980)
17. Strom B. Overview of automated databases in pharmacoepidemiology. In: Strom B, ed. Pharmacoepidemiology. West Sussex, United Kingdom: John Wiley & Sons Ltd; 2005: 219-222.
18. Stone M, Racoosin JA, Laughren T. Conventional vs. atypical antipsychotic medications [letter]. N Engl J Med. 2006;354(9): 972-974.
19. Walker AM. Confounding by indication. Epidemiology. 1996; 7(4):335-336.
20. Global Internet Management. SSDMF: Social Security Death Master File. Alexandria, VA: National Technical Information Service; 2006. (http://www.ssdmf.com). (Accessed May 3, 2010).
21. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075-1079.
22. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154(9): 854-864. (Pubitemid 33000813)
23. Greenland S, Rothman KJ. Introduction to stratified analysis. In: Rothman KJ, Greenland S, Lash T, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: LippincottWilliams &Wilkins; 2008:258-282.
24. Rassen JA, Brookhart MA, Glynn RJ, et al. Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol. 2009;62(12): 1233-1241.
25. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006; 163(12):1149-1156. (Pubitemid 43987579)
26. Greenland S. Introduction to regression modeling. In: Rothman K, Greenland S, Lash T, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:418-455.
27. Stürmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437-447.
28. Stürmer T, Rothman KJ, Avorn J, et al. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study. Am J Epidemiol. 2010;172(7):843-854.
29. Parsons L. Performing a 1:N case-control match on propensity score. (Paper 165-29). In : Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc; 2004.
30. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4): 512-522.
31. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf. 2010;19(6):537-554.
32. Brookhart MA, Wang PS, Solomon DH, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006; 17(3):268-275.
33. Mahalanobis P. On the generalized distance in statistics. Proc Natl Inst Sci India. 1936;2(1):49-55.
34. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5): 291-303. (Pubitemid 43797117)
35. Schneeweiss S, Setoguchi S, Brookhart M, et al. Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs. 2009;23(2):171-180.
36. Rothman K, Greenland S, Lash T. Validity in epidemiologic studies. In: Rothman KJ, Greenland S, Lash T, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:128-147.
37. Snowden M, McCormick W, Russo J, et al. Validity and responsiveness of the Minimum Data Set. J Am Geriatr Soc. 1999;47(8):1000-1004. (Pubitemid 29380495)
38. Hawes C, Morris JN, Phillips CD, et al. Reliability estimates for theMinimumData Set for nursing home resident assessment and care screening (MDS). Gerontologist. 1995;35(2): 172-178.
39. Bronskill SE, Rochon PA, Gill SS, et al. The relationship between variations in antipsychotic prescribing across nursing homes and short-term mortality: quality of care implications. Med Care. 2009;47(9):1000-1008.
40. Small DS, Rosenbaum PR. War and wages: the strength of instrumental variables and their sensitivity to unobserved biases. J Am Stat Assoc. 2008;103(483):924-933.